# Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies

> **NCT06648785** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **University of Vermont Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- GI Cancers

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** Fluoropyrimidine

## Key facts

- **NCT ID:** NCT06648785
- **Lead sponsor:** University of Vermont Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-21
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648785, "Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06648785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*